Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2026)
Emergent BioSolutions (EBS) posted quarterly Amortization of Deferred Charges of $1.8 million for Q1 2026, down 21.74% year-over-year from $2.3 million in Q1 2025, and down 30.77% quarter-over-quarter from $2.6 million in Q4 2025.
Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Emergent BioSolutions' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 21.74% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $9.3 million (up 232.14% YoY), while the FY2025 annual figure was $9.8 million, up 32.43% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $1.8 million, down from $2.6 million in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $8.9 million in Q2 2023, with the low at -$6.7 million in Q3 2024.
- The 5-year median for Amortization of Deferred Charges is $2.3 million (2025), against an average of $2.6 million.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges jumped 790.0% in 2023, then sank 217.54% in 2024.
- Emergent BioSolutions' Amortization of Deferred Charges stood at $1.0 million in 2022, then jumped by 470.0% to $5.7 million in 2023, then plunged by 61.4% to $2.2 million in 2024, then grew by 18.18% to $2.6 million in 2025, then tumbled by 30.77% to $1.8 million in 2026.
- Business Quant data shows EBS's Amortization of Deferred Charges at $1.8 million in Q1 2026, $2.6 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | -6.70 Mn |
| Sep 30, 2024 | -6.70 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 6.90 Mn |
| Mar 31, 2024 | 6.90 Mn |